Hartford多因子小型股ETF ROSC 深 沪
等待开盘 02-20 09:30:00 美东时间
50.8305
-0.046
-0.09%
华盛通- 最 高50.8305
- 今 开50.7984
- 成交量 1752股
- 最 低 50.6058
- 昨 收 50.8769
- 总市值 5083.05万
- 52周最高 51.38
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 34.7185
- 委 比 0.00%
- 总股本 100.00万
- 历史最高 51.38
- 量 比 0.70
- 振 幅 0.44%
- 历史最低 12.9823
- 每 手 1
- 风险率 3.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Firefly Neuroscience Inc May Offer, Sell Shares Of Common Stock Of Up To $7.4 Million From Time To Time
BRIEF-Firefly Neuroscience Inc May Offer, Sell Shares Of Common Stock Of Up To $7.4 Million From Time To Time Firefly Neuroscience Inc AIFF.O : FIREFLY NEUROSCIENCE INC: MAY OFFER, SELL SHARES OF COMMON STOCK OF UP TO $7.4 MILLION FROM TIME TO TIME Source text: [ID:n0001213900-26-011524] Further com
02-04 07:29
BRIEF-Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users
BRIEF-Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users Jan 28 (Reuters) - Jupiter Neurosciences Inc JUNS.O : JUPITER NEUROSCIENCES INC - ANNOUNCES STRATEGIC INITIATIVE FOR GLP-1 USERS Source text: ID:nGNX8RPntl Further company coverage: JUNS.O (( Reuters.Briefs@thom
01-28 19:02
BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial
Dec 18 (Reuters) - ProMIS Neurosciences Inc PMN.O: PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHASE 1B CLINICAL TRIAL OF PMN310 IN ALZHEIMER’S DISEASE PROMIS NEUROSCIENCES INC - INTE...
2025-12-18 20:39
BRIEF-Flow Neuroscience Reports FDA Approval Of Flow At-Home Brain-Stimulation Device For Treatment Of Major Depressive Disorder
Dec 11 (Reuters) - FLOW NEUROSCIENCE: FDA APPROVAL OF FLOW AT-HOME BRAIN-STIMULATION DEVICE FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER FLOW NEUROSCIENCE: EXPECTS FLOW AT-HOME BRAIN-STIMULATION DEVICE ...
2025-12-11 19:00
BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector
Dec 1 (Reuters) - MannKind Corp MNKD.O: MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF FUROSCIX READYFLOW™ AUTOINJECTOR FOR THE TREATMENT OF EDEMA IN AD...
2025-12-01 21:05
BRIEF-Minerva Neurosciences Appoints Dr. Inderjit Kaul To The Company’S Board Of Directors
Minerva Neurosciences Inc NERV.O: MINERVA NEUROSCIENCES APPOINTS DR. INDERJIT KAUL TO THE COMPANY’S BOARD OF DIRECTORS Source text: ID:nGNX36Q8wZ Further company coverage: NERV.O
2025-11-19 21:55
BRIEF-Maris-Tech Enters Quantum Navigation Field with Strategic Agreement to Develop Quantum-Based Gyroscope to Replace GPS Navigation
Nov 13 (Reuters) - Maris Tech Ltd MTEK.O: MARIS-TECH ENTERS QUANTUM NAVIGATION FIELD WITH STRATEGIC AGREEMENT TO DEVELOP QUANTUM-BASED GYROSCOPE TO REPLACE GPS NAVIGATION Source text: ID:nGNX4062PQ Fu...
2025-11-14 05:12
BRIEF-Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL in Parkinson’s Disease
Nov 5 (Reuters) - Jupiter Neurosciences Inc JUNS.O: JUPITER NEUROSCIENCES RECEIVES FDA CLEARANCE OF IND APPLICATION TO INITIATE PHASE 2A CLINICAL TRIAL OF JOTROL™ IN PARKINSON’S DISEASE JUPITER NEUROS...
2025-11-05 21:32
Biopharma MannKind's Q3 revenue up 17%
Overview MannKind Q3 2025 rev rises 17% yr/yr to $82.1 mln Adjusted EPS for Q3 2025 increases 45% from last year Company completes acquisition of scPharmaceuticals, boosting revenue growth Outlook Com...
2025-11-05 21:13
MannKind Corporation reports third quarter 2025 revenues of $82.1 million
MannKind Corporation reported third quarter 2025 revenues of $82.1 million, representing a 17% increase compared to the same period in 2024. Year-to-date 2025 revenues reached $237.0 million, up 14% f...
2025-11-05 21:04
